Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.
Smolen J.S., Beaulieu A., Rubbert-Roth A., Ramos-Remus C., Rovensky J., Alecock E., Woodworth T., Alten R., OPTION Investigators, 2008. Lancet, 371 (9617) pp. 987-997.
ici le détail